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Is the serum glucose/potassium 
ratio a reliable prognostic factor for 
aneurysmal SAH? 
TO THE EDITOR: We studied with keen interest 
the article by Fujiki et al.1 regarding the role of the se-
rum glucose/potassium ratio in predicting the outcome 
of aneurysmal subarachnoid hemorrhage (SAH) (Fujiki 
Y, Matano F, Mizunari T, et al: Serum glucose/potassium 
ratio as a clinical risk factor for aneurysmal subarachnoid 
hemorrhage. J Neurosurg [epub ahead of print November 
17, 2017. DOI: 10.3171/2017.5.JNS162799]). We commend 
the authors for their attempt to revisit this question be-
cause biomarkers for predicting poor prognosis following 
aneurysmal SAH have not yet been established. However, 
we would like to bring forth a few issues in this article that 
need further consideration. In their retrospective study 
design involving 565 subjects, they did not mention any 
inclusion or exclusion criteria. In their patient selection, 
there was no account of any pre-existing cause of hyper-
glycemia, which can be attributed to diabetes, metabolic 
syndrome, or insulin resistance. The drug status on admis-
sion—that is, taking oral hypoglycemic agents, insulin, or 
beta blockers—was not mentioned. The authors did not 
mention hypertensive status on admission or BMI in their 
summary of patient characteristics, which could have been 
potential confounders of a poor outcome.
There was no time cutoff from SAH to admission. 
The range of time from SAH to admission was 1 hour to 
16 days (mean time 20.1 ± 19.07 hours). Hence, the time 
from SAH to admission could be an independent factor 
affecting prognosis, with late admissions faring worse. 
Moreover, the authors did not mention whether it was a 
single value or a mean value of serum glucose or potas-
sium estimation at the time of admission. Also, there was 
no account of those patients who were normoglycemic 
at admission but later developed hyperglycemia. The au-
thors report that they used sliding scale insulin for post-
admission hyperglycemia control, but it would have been 
insightful to know the insulin dosage, which could high-
light the degree of hyperglycemia and metabolic stress. 
The study fails to answer a pertinent question, that is, 
whether the glucose/potassium ratio is associated with 
the risk of vasospasm/delayed cerebral injury. Moreover, 
no correlation of the serum glucose/potassium ratio with 
the Glasgow Outcome Scale (GOS) score at 3 months was 
assessed, which misses out on patients who could have 
delayed recovery. 
Finally, we would like to congratulate the authors on 
bringing to light an interesting scientific issue. Their ar-
ticle lays the groundwork for a larger prospective study 
design to evaluate these biomarkers in aneurysmal SAH 
to aid in treatment policy decisions.
Ravi Sharma, MBBS
Manoj Phalak, MCh
Prateek Sharma, MBBS
All India Institute of Medical Sciences, New Delhi, India
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Response
Thank you for your helpful comments regarding our 
article.
All patients with acute endogenous SAH (confirmed by 
CT or lumbar puncture) were eligible for study participa-
tion and were included if they or their health care decision 
surrogate provided consent. Patients with traumatic SAH 
and cardiopulmonary issues on arrival were excluded. 
Additionally, pre-existing hyperglycemia was defined by 
a history of diabetes, the use of oral hypoglycemic agents, 
the use of insulin, and an HbA1c value > 7.0. Among the 
565 treated patients, 46 had these conditions of pre-ex-
isting hyperglycemia. We found that 34 patients were us-
ing oral hypoglycemic agents, 3 were using insulin, and 5 
were using beta blockers. With regard to the hypertensive 
status and BMI of the patients, we did not find a significant 
correlation between a poor outcome (GOS scores 1–3) and 
these factors.
J Neurosurg 129:1098–1105, 2018
LETTERS TO THE EDITOR
Neurosurgical Forum
J Neurosurg Volume 129 • October 2018 1099
Neurosurgical forum
As you mentioned, for patients with severe SAH, the 
time from SAH to admission can be very important for 
deciding prognosis. However, patients with low-grade 
SAH, such as those who presented with mild headache, 
tended to undergo a late checkup at the hospital, resulting 
in a late admission. Thus, the data were uncorrelated with 
the time to admission. We apologize for not mentioning 
this information, but a single value of serum glucose or 
potassium was considered at the time of admission.
Ten patients were normoglycemic at the time of admis-
sion but later developed hyperglycemia. Among these 10 
patients, 7 (70.0%) had poor outcomes (GOS scores 1–3). 
However, the number of patients was not high enough to 
conclude a correlation with a poor outcome. Nevertheless, 
this situation should be considered.
With regard to the insulin dose, we believe that your 
point would have been insightful if we could show a corre-
lation. However, we think that it is difficult to judge wheth-
er a patient already has diabetes or whether the shock from 
SAH has caused hyperglycemia because some patients 
with diabetes who had not been diagnosed could have 
been included. Sixteen patients used sliding scale insulin 
for post-admission hyperglycemia control, and the insulin 
dose was 4–52 units (mean 22.4 ± 16.0 units). Among 8 
patients (50.0%) with poor outcomes (GOS scores 1–3), 5 
needed insulin doses over 30 units.
We are currently working on another paper about the 
association of the glucose/potassium ratio with the risk of 
vasospasm/delayed cerebral injury, and this paper will be 
submitted soon. We hope that this paper will provide fur-
ther clarification.
With regard to your last point, we have not provided in-
formation on that paper. However, we did analyze the cor-
relation between the serum glucose/potassium ratio and 
GOS score at 1 year after discharge in 413 patients. Based 
on the estimation of the GOS score at 1 year after dis-
charge, 180 patients (43.6%) were considered to have poor 
outcomes (GOS scores 1–3). There was a significant cor-
relation between poor outcomes at 1 year after discharge 
and the serum glucose/potassium ratio. This finding indi-
cates that we included patients who had delayed recovery.
Again, thank you for your helpful review of our article.
Yu Fujiki, MD 
Fumihiro Matano, MD, PhD 
Takayuki Mizunari, MD, PhD 
Yasuo Murai, MD, PhD 
Kojiro Tateyama, MD, PhD 
Kenta Koketsu, MD, PhD 
Asami Kubota, MD 
Shiro Kobayashi, MD, PhD 
Hiroyuki Yokota, MD, PhD 
Akio Morita, MD, PhD
Nippon Medical School, Tokyo, Japan
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A nonsignificant trial result does not 
mean that two procedures are equal
TO THE EDITOR: Vieira et al.1 contribute to the ac-
cumulating evidence on the commonly performed pro-
cedure of decompressive craniectomy by reporting the 
results of their randomized controlled study comparing 
2 surgical techniques for decompressive craniectomy 
(DC): with watertight duraplasty and without watertight 
duraplasty (Vieira E, Guimarães TC, Faquini IV, et al: 
Randomized controlled study comparing 2 surgical tech-
niques for decompressive craniectomy: with watertight 
duraplasty and without watertight duraplasty. J Neurosurg 
[epub ahead of print November 17, 2017. DOI: 10.3171/ 
2017.4.JNS152954]).
Although one must greatly appreciate such random-
ized controlled trials with blinded evaluation of outcomes, 
there are a few methodological flaws in the trial. The au-
thors give the impression that the experimental procedure 
is safe and hence equivalent to the traditional watertight 
cranioplasty. They come to the conclusion that rapid-clo-
sure DC without watertight duraplasty is a safe procedure 
and that it is not associated with a higher incidence of sur-
gical complications. Assuming that a procedure is equiva-
lent or non-inferior to another procedure just because 
there was no statistically significant difference is funda-
mentally wrong. Failure to reject the null hypothesis that 
the experimental procedure is not superior to the control 
procedure should not automatically prompt one to accept 
the null hypothesis and conclude that both procedures are 
equivalent in terms of safety.
In situations where one anticipates that one procedure 
is likely to be nearly equivalent to the other, as in the pres-
ent case, a non-inferiority trial design should be used. 
The authors describe a composite outcome of several 
complications, including CSF leak, subgaleal collection, 
and infective complications, as the primary outcome. The 
sample size should have been calculated to power the trial 
to find the primary outcome. However, the authors cal-
culated sample size to find a significant difference in the 
duration of the surgery, which resulted in extremely low 
power to detect superiority in terms of complications. A 
retrospective calculation shows that the trial had only 5% 
power to detect a statistically significant difference for the 
primary outcome.
Consider a hypothetical example in which the control 
arm has only 1 complicating event compared to the same 5 
complications that occurred in the experimental arm. The 
trial would still have shown no statistical significance! 
TABLE 1. Hypothetical example
Trial Arm Complications
No 
Complications Total
Control (watertight) 1 27 28
Experimental (non-watertight) 5 22 27
Total 6 49 55
The Fisher exact test statistic value is 0.101181 (not significant, p > 0.05). 
Neurosurgical forum
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(See Table 1.) Hence it is not correct to conclude that both 
arms are equal in terms of primary outcome.
Moreover, the safety concern that there could be more 
cortical damage when one has to release adhesions at the 
time of a future cranioplasty procedure still remains. The 
authors have proven that closure without watertight dura-
plasty is faster and cheaper—but not necessarily safe.
Gopalakrishnan Madhavan Sasidharan, MCh
Jawaharlal Insitute of Post-graduate Medical Education and Research, 
Pondicherry, India
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Response 
We appreciate the opportunity to respond to the com-
ments by Dr. Sasidharan. Indeed, the small number of pa-
tients in our study diminishes the impact of our results, as 
we state in the Discussion section of our article. Usually, 
when a rapid-closure (non-watertight dural closure) DC is 
performed, 3 concerns come to mind: infection, CSF leak, 
and adhesion/scarring between the cerebral parenchyma 
and the pericranium. Regarding the risk of infection, in 
our study, the DC with watertight dural closure had a 
significantly longer surgical time when compared to the 
rapid-closure (non-watertight) DC (132 vs 101 minutes). 
Several studies have shown that longer surgeries are as-
sociated with a higher incidence of complications, particu-
larly infectious complications.2,4,5 Surgeries lasting more 
than 120 minutes were associated with a 4-fold increased 
risk of surgical site infection.1 
In our study, overall complications were more com-
mon in the control group (with watertight dural closure, 
5 cases) and not in the rapid-closure group (4 cases), as 
Dr. Sasidharan points out. The incidence of CSF leak and 
subgaleal fluid collections (possibly representing the oc-
currence of CSF leaks contained by the skin closure) was 
also higher in the watertight dural closure group. Once the 
arachnoid is intact, there is no increased risk of CSF leaks. 
Moreover, attempts to achieve watertight closure may lead 
to small defects on suture lines, causing a “one-way valve” 
effect that could potentially facilitate the development of 
CSF leakage. Güresir et al.3 described a DC procedure 
that is similar to the one we used in our study. With a total 
of 341 procedures, they concluded that the rapid-closure 
technique did not increase the incidence of CSF leak, in-
fection, and/ or healing problems. 
Regarding cortical adhesions, after performing a rapid-
closure DC, the exposed brain parenchyma stays in con-
tact with the pericranium, which usually is dissected along 
with the myocutaneous flap during opening. Pericranium 
is widely accepted as an autologous graft when perform-
ing watertight dural closure after any neurosurgical proce-
dure. It is expected that the same degree of adhesion and 
scarring between the brain parenchyma and pericranium 
will occur, whether watertight duraplasty is performed or 
not. When performing cranioplasty, once the edges of the 
craniotomy are found, the myocutaneous flap can be eas-
ily dissected from this neo-formed fibrous layer that cov-
ers the brain parenchyma without pial injury. There is no 
need to expose the parenchymal surface. Güresir et al., in 
a retrospective analysis of 196 cranioplasties after rapid-
closure DC, found no higher incidence of complications.3 
Eduardo Vieira, MD
Igor V. Faquini, MD
Nivaldo S. Almeida, MD
Hildo R. C. Azevedo-Filho, Msc, PhD, FRCS
Hospital da Restauração, Recife, Brazil
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Low ICP and normal tension 
glaucoma: optic nerve damage due to 
barotraumatic factors, failure of CSF 
dynamics, or both?
TO THE EDITOR: We read with great interest the ar-
ticle by Gallina et al.2 (Gallina P, Savastano A, Becattini 
E, et al: Glaucoma in patients with shunt-treated normal 
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pressure hydrocephalus. J Neurosurg [epub ahead of print 
November 17, 2017. DOI: 10.3171/2017.5.JNS163062]). We 
appreciate the authors’ study and their efforts to explore 
the role of low intracranial pressure (ICP) in the patho-
genesis of normal tension glaucoma (NTG). However, we 
feel that an issue described in their paper deserves further 
discussion.
As discussed by the authors, several studies have pro-
vided clinical evidence in support of the theory that re-
duced ICP may play a role in the pathogenesis of NTG.1 In 
line with this theory, they demonstrate that patients whose 
ICP has been lowered following ventriculoperitoneal shunt 
placement, as treatment for normal pressure hydrocep-
halus, are almost 40 times more likely to suffer from NTG 
than elderly Italian patients without hydrocephalus.2 The 
mechanisms most commonly proposed to explain the con-
tribution of low ICP and thus a high trans–lamina cribrosa 
pressure difference (intraocular pressure - ICP) to glauco-
ma are direct strain on the lamina cribrosa, impairment of 
axonal transport, and altered blood flow.1 The authors cite 
one of our papers,10 which focused on the possible role of 
cerebrospinal fluid (CSF) circulatory dysfunction in NTG, 
and argue against our hypothesis stating that “the finding 
that NTG occurs in patients whose CSF clearance was 
forced more strongly by the sink action of the diversion 
does not support, as already noted, a pres sure-independent 
pathogenetic hypothesis, which focuses on the accumula-
tion of toxins at the level of the optic nerve due to failure 
of CSF dynamics.”2 For the reasons set forth below, we 
respectfully disagree with this statement.
Evidence in support of our viewpoint comes from a re-
cent dog study by Hou et al.3 During CSF shunting from 
the brain ventricle, the intraventricular ICP gradually de-
creased in a linear fashion together with the optic nerve 
subarachnoid space (SAS) pressure.3 But when the ICP 
fell below a critical breakpoint, optic nerve SAS pressure 
remained constant despite further ICP decline.3 These 
authors interpreted this as a sign of CSF communication 
arrest between the intracranial and optic nerve SAS.3 In-
deed, when ICP drops too low, the breakpoint is reached 
and CSF flow stops.3 This means that the ICP is too low 
for CSF to freely flow through the optic canal.3 
Intriguingly, the findings by Hou et al.3 may bring to-
gether two seemingly very different theories of glaucoma 
pathogenesis. Berdahl and Allingham,1 as well as others,9 
have suggested that the lower ICP reported in glaucoma 
patients could play a role in the pathogenesis of the disease 
through a higher pressure difference across the lamina cri-
brosa, influencing the physiology and pathophysiology of 
the optic nerve head. However, it should be noted that the 
clinical retrospective and prospective studies of CSF pres-
sure in patients with glaucoma have taken the lumbar CSF 
pressure measurement as a surrogate for the retrolamin-
ar CSF pressure1 and that the true CSF pressure behind 
the lamina cribrosa is not known.7 Furthermore, two re-
cent studies did not confirm lower ICP in NTG patients.5,8 
Killer et al.4 suggested that open-angle glaucoma may be 
due to the sequestration of CSF within the terminus of the 
optic nerve SAS, creating a stagnant region accumulating 
substances toxic to the adjacent optic nerve head. Wostyn 
et al.10 proposed that decreased ICP and an optic nerve 
sheath compartment syndrome could be seen as sequen-
tial steps in the disease process of NTG. The dog study by 
Hou et al.3 indeed suggests that if the ICP is too low, CSF 
flow from the intracranial SAS into the optic nerve SAS 
stops and CSF drainage from the optic nerve SAS is in-
terrupted as well, creating a CSF compartment syndrome. 
Compartmentation of the optic nerve SAS seems to be as-
sociated with a narrower optic canal cross-sectional area 
in NTG patients.6
Given the above considerations and given that both the 
hydrostatic pressure and the dynamics of CSF may be of 
great importance for the physiological stability of the op-
tic nerve,11 we believe that the pressure gradient with shear 
stress at the site of the lamina cribrosa may be accompa-
nied by another mechanism, namely toxicity of non-recy-
cled CSF around the optic nerve. 
Peter Wostyn, MD1
Veva De Groot, MD, PhD2
Debby Van Dam, PhD3,4
Kurt Audenaert, MD, PhD5
Peter Paul De Deyn, MD, PhD3,4,6
Hanspeter Esriel Killer, MD7
1PC Sint-Amandus, Beernem, Belgium
2Antwerp University Hospital, Antwerp, Belgium 
3Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, 
University of Antwerp, Antwerp, Belgium 
4University of Groningen and University Medical Center Groningen, 
Groningen, The Netherlands 
5Ghent University Hospital, Ghent, Belgium 
6Middelheim General Hospital (ZNA), Antwerp, Belgium
7Kantonsspital Aarau, Aarau, Switzerland 
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Response
We are pleased regarding the letter by Wostyn et al. be-
cause it gives us the possibility of critically checking our 
contention that a lowering of ICP underlies optic nerve 
damage in shunted normal pressure hydrocephalus. Those 
results support the role of changes in intraocular pressure 
and ICP gradient across the lamina cribrosa in the patho-
physiology of NTG.20
The arguments by Wostyn et al. descend from experi-
mental findings in dogs,7 in which CSF circulation at the 
level of the optic nerve SAS is halted when ICP falls below 
a critical breakpoint value. According to Hou et al.,7 this 
would involve CSF segregation, thus preventing the supply 
of nutrients to, and the disposal of waste molecules from, 
the so-called optic nerve chamber.10,11 Wostyn et al. dis-
puted that these findings would put into question our infer-
ence that the failure of CSF dynamics cannot explain the 
occurrence of NTG in precisely those patients with lower 
opening pressure valve values, where CSF clearance was 
forced by the stronger sink action of the diversion. Con-
sequently, we argued that a pressure-independent patho-
genetic hypothesis based on the accumulation of toxins at 
the level of the optic nerve due to CSF circulation failure21 
cannot apply to our data because a higher CSF clearance 
would prevent stagnation of CSF.
Admittedly, because of the obvious anatomical-phys-
iological differences, it is difficult to straightforwardly 
translate the results obtained in dogs into human beings. 
However, dogs have been widely used to study CSF hydro-
dynamics since the classic work of Dandy and Blackfan.4 
Therefore, it was tempting to play along, and we noted that 
our NTG patients underwent a lowering of ICP within the 
ICP-dependent zone identified by Hou et al.,7 where the 
intraventricular values decreased linearly with optic nerve 
SAS pressure. As a consequence, our patients experienced 
optic nerve damage even though the hypothetical arrest of 
communication between the intracranial and optic nerve 
SAS would not have occurred yet.
Recent anatomical evidence supports the notion that 
free circulation of CSF within the optic canal in humans 
may be hampered,16,17 leading to compartmentalization of 
the SAS within the canalicular portion and the accumula-
tion of toxins, possibly causing NTG.11 Liugan et al.16 re-
vealed the fibrous components within the optic canal and 
their relationship with the optic nerve SAS, which are sug-
gestive of a valve mechanism at work in CSF sequestra-
tion.12 A bony bottleneck responsible for CSF circulatory 
dysfunction was advocated by Pircher et al.,17 who showed 
that the optic canal, as measured in the coronal plane at the 
orbital opening, is smaller in NTG patients than in con-
trols. These results were paralleled by MRI data showing 
lower CSF flow between the intracranial cavity and optic 
nerve SAS in NTG patients compared to that in healthy 
controls.3 Overall, these findings shift the anatomical-
physiological site of NTG pathogenesis far from the lamina 
cribrosa, the structure where an increased pressure gradi-
ent between the intraocular and intracranial compartments 
would act and damage the optic nerve.20 Moreover, Wostyn 
et al. put forward two recent studies14,18 that reported no 
ICP decrease, as measured by lumbar puncture, in white 
NTG patients, suggesting that the current view20 of the 
trans–lamina cribrosa gradient hypothesis should at least 
be reconsidered. However, Pircher et al.18 performed a ret-
rospective study without a control group, which limits the 
generalizability of their results. Moreover, these studies14,18 
share two more weaknesses: 1) lumbar CSF pressure is 
not accurate enough to extrapolate ICP around the optic 
nerve,9 and 2) both involved white patients—which could 
explain the discrepancy between their results and those of 
Ren et al.,19 who studied an Asian population. Nonethe-
less, recent advances in ultrasound technology have al-
lowed higher-resolution images of the optic nerve SAS to 
be generated, enabling more detailed measurements and 
increased power to predict CSF pressure at that level.15 
Liu et al. demonstrated that NTG patients had a significant 
smaller optic nerve SAS than healthy controls, a finding 
that was indicative of lower CSF pressure and suggestive 
of an abnormally high trans–lamina cribrosa pressure dif-
ference in the NTG group.15
In fact, the pathophysiology of NTG remains incom-
pletely understood. Both the barometric and the CSF dy-
namics failure hypotheses are supported by bodies of evi-
dence. Intriguingly, Wostyn et al. propose a reconciliation 
between the two theories and advance a stepwise nature 
for the disease. Wishing to follow the advice from Wostyn 
et al., we plan to check the possible concomitance of some 
features supporting the CSF compartment syndrome at 
the optic nerve SAS in our normal pressure hydrocepha-
lus patients whose ICP was lowered by a CSF shunt. We 
will simply look at possible differences in the size of the 
optic canal17 between NTG and no-NTG groups. If the 
mechanism involved in NTG occurrence in these patients 
is related to the lowering of ICP, as we have argued, a nar-
rowing of the optic canal should not be expected. Indeed, 
the trans–lamina cribrosa pressure difference hypothesis 
assumes free communication between the intracranial CSF 
spaces and the lamina cribrosa, which is, in fact, poste-
riorly displaced in NTG,13 while a canalicular bottleneck 
would limit the transmission of ICP through the SAS. It 
is worth noting that severe papilledema and poor visual 
function were associated with a larger optic canal in 69 
patients with idiopathic intracranial hypertension,2 while 
J Neurosurg Volume 129 • October 2018 1103
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a smaller size was associated with the less affected side in 
8 patients with asymmetrical papilledema.1 Further clini-
cal studies may also assess possible age differences among 
NTG patients in relation to optic canal size. In this regard, 
it has been shown that optic canal volume decreases with 
aging.6 Pircher et al.17 could not detect a significant cor-
relation between optic canal size and age in either the 
NTG group or the control group. However, it should be 
noted that their samples were dimensionally inadequate 
to appreciate small effect sizes. For the sake of specula-
tion, we considered the data of Pircher et al.17 and found 
that their youngest (age < 60 years) NTG patients had a 
smaller optic canal size than those measured in their old-
est (age > 80 years) NTG patients. The opposite was true 
for their controls, in whom the size of the optic canal of 
the oldest subjects was narrower than that measured in the 
youngest group. These inverse correlations between NTG 
and controls were especially valid for males. Therefore, 
the question is far from being settled, especially if ethnic 
differences come into play. Notably, optic canal measure-
ments in Chinese patients showed larger cross-sectional 
areas compared to those in whites.8,17 Nevertheless, if an 
anatomical narrowing of the optic canal predisposes to an 
impairment of CSF flow in the optic nerve SAS, which can 
now be assessed in a noninvasive manner,3 CSF compart-
mentalization would occur early. As a consequence, the 
damage to the optic nerve would appear in the absence of 
intracranial hypotension, which is an age-related process.5 
On the other hand, in the presence of a relatively large optic 
canal, NTG occurrence might be expected to be a process 
related to aging. In this light, the temporal dimension and 
anatomical interindividual variation at the level of the optic 
canal may ultimately make someone more liable to either 
barometric damage at the lamina cribrosa or to stagnation 
of toxic substances within the compartmentalized optic 
canal SAS. Undoubtedly, much experimental and clinical 
knowledge is still needed to understand which one of these 
mechanisms underlies NTG and if they operate together or 
alternatively.
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Phase III randomized controlled 
trials are essential to properly 
evaluate the role of radiotherapy in 
WHO grade II meningioma
TO THE EDITOR: We read the study by Rogers et al.7 
(Rogers L, Zhang P, Vogelbaum MA, et al: Intermediate-
risk meningioma: initial outcomes from NRG Oncology 
RTOG 0539. J Neurosurg 129:35–47, July 2018). Inter-
mediate-risk meningiomas were defined as those with a 
higher recurrence rate and include WHO grade II menin-
giomas (Simpson grades I–III) that had undergone gross-
total resection (GTR) and any recurrent WHO grade I 
meningioma, regardless of the extent of resection. Despite 
the relative radioresistance of meningiomas, radiotherapy 
remains the only available adjuvant therapy for these tu-
mors; in WHO grade II meningioma, there is a lack of 
class I evidence for the role of early adjuvant radiotherapy.5 
Treatment decisions (i.e., adjuvant radiotherapy vs no 
adjuvant radiotherapy) after surgery currently factor in 
tumor location, the patient’s pretreatment characteristics, 
and the willingness of the surgeon to reoperate if there is a 
recurrence.4 Tumor recurrence undoubtedly has an impact 
on patient quality of life, and, if adjuvant radiotherapy can 
deliver prolonged control with low risk, it should be con-
sidered in the multimodality management of WHO grade 
II meningiomas. RTOG 0539 was a phase II nonrandom-
ized study with a primary endpoint of 3-year progression-
free survival and included 36 patients with GTR grade II 
meningiomas who received postoperative radiotherapy; 
of these patients, one patient’s disease progressed and an-
other patient died of the disease, resulting in a 3-year local 
failure rate of 4.1%. It is reassuring to note that the early 
adverse events (from radiotherapy) were limited to Com-
mon Terminology Criteria for Adverse Events grade 1 or 2 
(mainly dermatological) with no severe events.
 Neurosurgeons have been historically skeptical about 
adjuvant radiotherapy, citing concerns about the risk of 
late cognitive decline, which is also a concern for patients.8 
It is also reassuring that the RTOG 0539 study reported 
that mild memory decline affected only a small number 
of patients, although detailed cognitive assessment was 
not performed. Likewise, another phase II trial performed 
by the European Organisation for the Research and Treat-
ment of Cancer (EORTC 22042-26042) did not show any 
cognitive impact after high-dose radiotherapy and similar 
control rates (D.C. Weber, personal communication). The 
relatively mild adverse events may be attributable to better 
radiotherapy planning techniques that minimize the radio-
therapy dose to normal brain;1 however, it is important to 
emphasize that both phase II studies had only 3 years of 
follow-up and later meningioma recurrence may occur. 
The lack of a control arm is the main limitation of 
the study, and neurosurgeons are likely to remain skepti-
cal about adjuvant radiotherapy for GTR WHO grade II 
meningioma. Nevertheless, the favorable adverse event 
profile of radiotherapy supports the continued enrollment 
into open phase III studies. The Radiation versus Obser-
vation following Surgical Resection of Atypical Menin-
gioma (ROAM)/EORTC 1308 trial (ISRCTN71502099) is 
a multicenter, phase III, randomized controlled trial that 
will answer the following question: In patients who have 
undergone GTR of atypical meningioma, does early adju-
vant radiotherapy reduce recurrence compared to active 
monitoring?3 The study is open across the United King-
dom, Europe, Australia, and New Zealand (http://roam-
trial.org.uk), with 44 sites open (63 planned) and 36 pa-
tients randomized (190 planned). The study is powered to 
detect an absolute reduction in recurrence rate from 40% 
(control arm) to 20% (radiotherapy arm) at 5 years and 
importantly will collect data on quality of life and neuro-
cognitive function and assess whether adjuvant radiother-
apy is cost-effective. Studies of intervention versus moni-
toring can pose a recruitment challenge since clinicians 
and patients often exhibit bias.2,6 Preliminary results from 
the embedded qualitative research study of audio record-
ings of the recruitment consultation have led to improve-
ments by researchers in balancing the treatment arms and 
explaining equipoise. In parallel the NRG BN-003 study 
(http://clinicaltrials.gov/ct2/show/NCT03180268) will also 
provide class I evidence. 
It is incumbent on the neurosurgery and oncology com-
munity to work collaboratively to ensure both trials are 
successfully delivered in order to establish the best way to 
manage patients with complete resection of WHO grade II 
meningioma.
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